121 results about "Hepatocellular Cancers" patented technology

A cDNA molecule corresponding to a newly discovered human gene is disclosed. The new gene, which is frequently deleted in liver cancer cells and cell lines, is called the DLC-1 gene. Because the gene is frequently deleted in liver cancer cells, but present in normal cells, it is thought to act as a tumor suppressor. This gene is also frequently deleted in breast and colon cancers, and its expression is decreased or undetectable in many prostate and colon cancers. Also disclosed is the amino acid sequence of the protein encoded by the DLC-1 gene. Methods of using these biological materials in the diagnosis and treatment of hepatocellular cancer, breast cancer, colon cancer, prostate cancer, and adenocarcinomas are presented.

The invention belongs to the technical field of molecular biology and biomedicine and in particular relates to application of a gRNA (guide Ribonucleic Acid) sequence based on a CRISPR / Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats / CRISPR associated protein 9) system on knockout of a human Lin28A gene and application to tumor treatment. According to a design principle of CRISPR / Cas9, 6 guide RNAs (gRNA) are designed and a sequence table is shown as SEQ ID NO.1 to SEQ ID NO.6; the guide RNAs are constructed on a PX458 carrier and two efficient target gRNAs are obtained through activity detection and screening. The CRISPR / Cas9 system guided by the two gRNAs is utilized in human hepatocellular carcinoma cell lines (HepG2) and human melanoma cell lines (A375), and the human Lin28A gene can be effectively knocked out; the system is easy to operate and the human Lin28A gene knockout efficiency is high, so that the system is applicable to various tumor cell models. The gRNA provided by the invention is hopefully applied to a new drug for treating tumors.

The invention discloses a hepatocellular carcinoma automatic grading method based on an SE-DenseNet deep learning framework and an enhanced MR image. The method comprises the following steps of 1) collecting data; 2) preprocessing all hepatocellular carcinoma three-dimensional images with enhanced MR; 3) enhancing the training data; 4) based on the enhanced training data, training a hepatocellularcarcinoma grading prediction model, namely an SE-DenseNet network; and 5) carrying out hierarchical prediction on the test data by adopting the trained model, and evaluating the classification performance of the hepatocellular carcinoma hierarchical prediction model. According to the automatic pathological grading method for the hepatocellular carcinoma multi-modal enhanced MR image which is composed of the steps of image preprocessing, the image enhancement, the hepatocellular carcinoma multi-modal enhanced MR image classification, SE-DenseNet network training and SE-DenseNet network testing, the hepatocellular carcinoma automatic grading can be realized, and the problems of manpower consumption, time consumption and subjective difference existing in manual hepatocellular carcinoma grading can be solved.

The invention features a method for determining methyl transferase activity of a polypeptide and screening for modulators of methyl transferase activity. The invention further provides a method or pharmaceutical composition for prevention or treating of colorectal cancer or hepatocellular carcinoma using the modulator.

The invention relates to a human asialoglycoprotein receptor (ASGPR) monoclonal antibody as well as a preparation method and application thereof. The monoclonal antibody can be used for well recognizing an ASGPR antigen, cannot perform cross reaction with other proteins, and is very high in specificity and sensitivity. The antibody disclosed by the invention can be applied to identification of primary hepatocellular carcinoma and metastatic liver cancer, separation and detection of circulating liver cancer cells, liver imaging and targeted delivery of liver medicines or genes.

This invention provides methods for detecting serum GEP level. This invention further provides methods for determining whether a subject is afflicted with Hepatocellular carcinoma (HCC) by measuring serum GEP level. In another embodiment, this invention provides methods for the suppression of HCC growth and progression both in vitro and in vivo by treating a patient with anti-GEP monoclonal antibody A23.

The invention discloses nucleic acid for treating HCC (Hepatocellular Carcinoma), a preparation method thereof, a CAR-T (Chimeric Antigen Receptor T) cell having the nucleic acid and a preparation method of the CAR-T cell. A sequence of the nucleic acid at least comprises a CD226 costimulatory zone nucleic acid sequence as shown in SEQ ID NO.6 and a 4-1BB costimulatory zone nucleic acid sequence as shown in SEQ ID NO.7. An inhibition function of an HCC microenvironment can be overcome by promoting the generation of cell factors of IFN (Interferon)-gamma, so that the infiltration rate, the proliferation rate and the survival rate of T cells can be increased; after GPC3-226BB-CART cells are injected to a body, the GPC3-226BB-CART cells can survive in tumor and can be continuously proliferated until the tumor is removed.

The invention belongs to technical field of genes, and relates to a long non-coding RNA AY927503 and application thereof. It is proved through experiments that the long non-coding RNA AY927503 can adjust migration of human hepatocellular carcinoma cells, sulfatide can adjust migration of the human hepatocellular carcinoma cells through the long non-coding RNA AY927503, express of integrin alpha V can be adjusted, and the long non-coding RNA AY927503 can adjust migration of the cells through the integrin alpha V; it is proved through experiments that the long non-coding RNA AY927503 is mainly located in cytoplasm and also exists in cell nuclei, the long non-coding RNA AY927503 can adjust the activity of a promoter of the integrin alpha V, and the long non-coding RNA AY927503 is not combined with a transcription factor on the promoter of the integrin alpha V but is directly combined with the promoter of the integrin alpha V. According to the long non-coding RNA AY927503 and the application thereof in gene control, the long non-coding RNA AY927503 can be directly combined with the promoter of the integrin alpha V, adjust the transcriptional activity of the integrin alpha V and then influence the behavior of the cells; the long non-coding RNA AY927503 can be used for preparing a target molecule of the human hepatocellular carcinoma cells.

Methods are provided for detecting a cell proliferative disorder associated with TSLC1 by contacting a proliferating cell of a subject suspected of having the disorder with a reagent that detects TSLC1 and detecting the level of TSLC1 in the proliferating cell. TSLC1 is a single gene whose expression is reduced or absent in A549 and some other NSCLC, hepatocellular carcinoma and pancreatic cancer cell lines. It has further been discovered that TSLC1 expression or suppression is perfectly correlated with promoter methylation state. Restoration of TSLC1 expression to normal or higher levels is sufficient by itself to suppress tumor formation. The invention further provides methods of treating such disorders by contacting cells of a patient suffering from the disorder with a therapeutically effective amount of a reagent that modulates TSLC1 level in the proliferating cells.

It is disclosed herein that miR-221 and miR-222 down-regulate PTEN and TIMP3 tumor suppressors, resulting in TRAIL resistance. The present invention provides research, diagnostic, and therapeutic tools and methods related to this discovery. Diagnostics, prognostics and treatments for human hepatocellular cancer and non-small cell lung carcinoma having a TRAIL resistance are particularly described herein.

The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (LEPR), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR and antagonize LEPR signaling. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR in the presence or absence of leptin. In other embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that exhibit partial agonism of LEPR signaling. The antibodies and antigen-binding fragments of the present invention are useful for the treatment of various conditions, including but not limited to congestive heart failure cachexia, pulmonary cachexia and cancer cachexia, autoimmune disorders such as inflammatory bowel disease, lupus erythematosus, multiple sclerosis, psoriasis, cardiovascular diseases, elevated blood pressure, neurodegenerative disorders, depression, cancer such as hepatocellular carcinoma, melanoma, breast cancer, and other diseases and disorders associated with or caused by elevated leptin signaling.

The present invention relates to a gastroretentive tablet for treating unresectable hepatocellular carcinoma, comprising an enteric polymer, a nanoparticle and an excipient, wherein the nanoparticle comprises an oral multikinase inhibitor, wherein the oral multikinase inhibitor is coated with an amino methacrylate copolymer, wherein the oral multikinase inhibitor is sorafenib, and wherein the enteric polymer is methacrylic acid copolymer. The excipient is selected from a group consisting of a retarding agent, a binder, a filler, a diluent, a disintegrant, a lubricant, a colorant, a solubilizing agent, or a mixture thereof.

The present invention addresses the problem of providing a hepatocellular carcinoma marker which can be used for detecting the presence of hepatocellular carcinoma and comprises a glycoprotein that can occur in the liver only when the carcinoma is developed regardless of the change in the condition of the liver. The present invention provides a hepatocellular carcinoma marker which comprises an NPA lectin-binding glycoprotein containing an NPA lectin-binding sugar chain epitope having at least one property selected from the following properties (1) to (5) (1) the sugar chain epitope does not contain core fucose (a fucose alpha 1(arrow) 6 sugar chain); (2) the sugar chain epitope contains a composite sugar chain that contains three (less than four) mannose molecules; (3) the sugar chain epitope does not contain a high-mannose-type sugar chain containing five or more mannose molecules; (4) the sugar chain epitope comprises a composite sugar chain that does not rely on the bindability to LCA lectin; and (5) the sugar chain epitope comprises a composite sugar chain that does not rely on the bindability to ConA lectin. The presence of the development of hepatocellular carcinoma or the degree of the progression or malignancy of the carcinoma can be determined by detecting the hepatocellular carcinoma marker of the present invention in a sample of interest.

The present invention provides compounds useful in the treatment and prophylaxis of infection in mammals and avian species by pathogenic agents such as, but not limited to, viruses. The present invention further provides compounds useful in the treatment of other disease conditions such as cirrhosis and hepatocellular carcinoma. The present invention further provides methods for diagnosing infection by pathogenic organisms and viruses or other disease conditions and agents useful in diagnostic protocols. The present invention further contemplates methods for monitoring disease states and providing an indication of the susceptibility of a subject for infection by a pathogenic organism or virus or development of other diseased states. In particular, the present invention enables a determination of whether, including a prediction of the level of likelihood that, a subject will respond to therapeutic or prophylactic intervention of an infection or disease condition.

The invention discloses compounds represented by a general formula (I) shown in the description, wherein in the formula (I), A and B are respectively a six-membered cyclic compound containing D1, D2,D3 and D4 and a six-membered cyclic compound containing D5, D6, D7 and D8. The invention also disclose an indoleamine-2,3-dioxygenase and / or tryptophan-2,3-dioxygenase inhibitor containing the above compounds and the application of the compounds in preparation of medicaments for treating cancers. The compounds provided by the invention can effectively inhibit cell proliferation, and have good therapeutic effects on various diseases such as the cancers, significant therapeutic effects on breast cancer, cervical cancer, colon cancer, lung cancer, stomach cancer, rectal cancer, pancreatic cancer,brain cancer, skin cancer, oral cancer, prostate cancer, bone cancer, kidney cancer, ovarian cancer, bladder cancer, liver cancer, fallopian tube tumors, ovarian tumors, peritoneal tumors, stage IV melanoma, glioma, neuroblastoma, hepatocellular carcinoma, mastoid renal tumors, head and neck tumors, leukemia, lymphoma, myeloma and non-small cell lung cancers, and very broad application prospects.

It is disclosed herein that miR-221 and miR-222 down-regulate PTEN and TIMP3 tumor suppressors, resulting in TRAIL resistance. The present invention provides research, diagnostic, and therapeutic tools and methods related to this discovery. Diagnostics, prognostics and treatments for human hepatocellular cancer and non-small cell lung carcinoma having a TRAIL resistance are particularly described herein.

The invention discloses an automatic liver tumor classification method and device based on physiological indexes and image fusion so that good robustness is realized for different patients during identification. A complex feature extraction algorithm does not need to be artificially designed . Full-automatic feature learning and extraction are realized, combined learning and mining are carried out on feature expression differences of the bile duct cell carcinoma and the hepatocellular carcinoma on images and expression differences of the bile duct cell carcinoma and the hepatocellular carcinoma on physiological indexes, and identification accuracy of the model is improved. The method comprises the following steps: constructing an image and physiological index database of bile duct cell carcinoma and hepatocellular carcinoma, and collecting an abdomen CT image of a patient and corresponding physiological indexes recorded by a doctor; marking all the acquired image data, drawing a livertissue area in the image data, judging whether the liver tissue area belongs to the cholangiocarcinoma or the hepatocarcinoma, and marking the liver tissue area as a gold standard for network training; constructing a three-dimensional full convolutional neural network segmentation model; and constructing a deep convolutional neural network classification model based on image and physiological index fusion.

The invention provides a biomarker for early diagnosis of primary hepatocellular carcinoma as well as a detection reagent and application of biomarker, and belongs to the technical field of liver cancer diagnosis. According to the invention, bacterial DNA is extracted from an excrement sample of a detected object by a 16S rRNA sequencing method; then, Illumina Miseq sequencing is carried out; intestinal biomarkers for early liver cancer and healthy control are identified; furthermore, a random forest model for specifically identifying early liver cancer and healthy population samples is established through the biomarkers; a fitting condition of a learning curve evaluation model is drawn; the effect of the model is evaluated through a receiver operating characteristic curve; the area under the curve of the prediction model is 0.95; the precision of the test result is 0.97; the recall rate is 1.0; and the specificity is 0.98. Therefore, the biomarker, the built random forest training model and the detection method in the invention have a good market prospect in early diagnosis of liver cancer.

The invention discloses a small-molecular RNA gene hsa-miR-101 relevant to a primary hepatocellular carcinoma as well as an application thereof. The invention also provides a method for analyzing the correlation between the small-molecular RNA gene and the tumor formation and development, as well as purposes of the small-molecular RNA gene hsa-miR-101 at the aspect of primary liver cancer treatment. The invention aims to provide the small-molecular RNA gene hsa-miR-101 acting as the application of tumor therapeutic drugs, and has great practical significance and broad applying prospect in the medical and biopharmaceutical fields.

The invention discloses a monoclonal antibody or sections thereof, which is sieved by utilizing a bacteriophage antibody database technology and prepared by utilizing a gene engineering method, of VEGFR2, and also discloses a carrier containing polynucleotide, which codes the monoclonal antibody or sections thereof, host cells, a method of preparing and purifying, and applications. The monoclonal antibody or sections thereof is used for preparing medicines for curing diseases caused by cancer new-born blood vessels. The diseases contain but not limited to following cancers: non-small cell lung cancer, metastatic non-small-cell lung cancer, hepatocellular carcinoma, metastatic hepatocellular carcinoma, HER2 negative metastatic breast cancer, metastatic gastric gland cancer, metastatic colorectal cancer, metastatic melanoma, and metastatic renal cell carcinoma.

The present invention discloses a new specific antibody (humanized monoclonal antibody huSM5-1 and human-mouse chimeric antibody SM5-1) specific for melanoma, breast cancer and hepatocellular carcinoma, and its related antigen encodes the Isolated nucleic acid molecules of antibodies, and methods of making said antibodies. The present invention also relates to the application of the antibody and / or isolated nucleic acid molecule in the preparation of medicaments for diagnosing and treating malignant tumors.

The invention discloses a method for establishing a liver cancer diagnosis model based on liver cancer triple detection. The method comprises the following steps of: 1, establishing a primary hepatocellular carcinoma database of primary hepatocellular carcinoma clinical characterization and laboratory data, and collecting laboratory indexes of a patient; and 2, arranging laboratory indexes, and establishing a multi-factor Logistic regression model to obtain a liver cancer diagnosis model. The laboratory indexes of the liver cancer diagnosis model CGALAD comprise the basic information gender and age of a patient, and liver cancer serological marker alpha fetoprotein heteroplasmon, alpha fetoprotein and abnormal prothrombin. Laboratory indexes of the liver cancer diagnosis model LAD compriseliver cancer serological marker alpha fetoprotein heteroplasmon, alpha fetoprotein and abnormal prothrombin. Parameters of the two liver cancer diagnosis models are easy to obtain, the parameters areon the same inspection subdisciplinary detection platform, a single report unit is few, influence factors are few, so that the clinical applicability and feasibility of the method are high.

The invention discloses a long non-coding RNA and application thereof in diagnosis and treatment of hepatocellular carcinoma. The long non-coding RNA is long non-coding RNA lncRNA MAPKAPK5-AS1, a gene ID of the long non-coding RNA is ENSG00000234608, the long non-coding RNA is positioned at 12q24.12, and a nucleotide sequence of the lncRNA MAPKAPK5-AS1 is shown as Seq ID NO.1. The invention finds that the lncRNA MAPKAPK5-AS1 can be used as a diagnostic biomarkerand a drug treatment target for hepatocellular carcinoma for the first time, and provides that an MAPKAPK5-AS1 / PLAGL2 / HIF-1alpha loop can be used as a diagnosis and treatment target for hepatocellular carcinoma. The lncRNA MAPKAPK5-AS1 is obviously up-regulated in hepatocellular carcinoma tissues, and MAPKAPK5-AS1 inhibition can be used for inhibiting proliferation, migration and EMT of HCC cells and inducing apoptosis.

The invention discloses methylated sites of liver-cancer-related human genes NUDT2 and PCDH8 and applications of the methylated sites of the human genes NUDT2 and PCDH8. According to the methylated sites and the applications, a pyrosequencing method is adopted for quantitatively detecting the methylation level of the specific site cg04322134 of the NUDT2 gene and the site cg20366906 of the PCDH8 gene, a unique primer is designed aiming at each site, and the primers comprise upstream and downstream PCR amplification primers and a pyrosequencing primer, wherein one of the amplification primers is provided with a biotin label. The rapid and accurate quantitative detection can be carried out on the methylation level of the specific sites of the genes NUDT2 and PCDH8, and the result shows that the methylation level of the two sites has obvious change in primary hepatocellular carcinoma patients.

Disclosed herein is a method for determining the prognosis of a subject diagnosed with hepatocellular carcinoma based on the expression level of at least one microRNA in the non-cancerous liver tissue of the subject. According to various embodiments of the present disclosure, expression levels of miR-486-3p, miR-876-5p, and miR-381 are positively associated with a favorable prognosis, while expression levels of miR-30c, miR-432, and miR-15b are negatively associated with a favorable prognosis.

The invention provides a biflavonoid compound. The compound has a structural formula shown in the description. The invention also provides a preparation method of the biflavonoid compound, and relatesto a pharmaceutical preparation containing the biflavonoid compound and an application of the biflavonoid compound in preparation of a medicine for treating hepatocellular carcinoma and a medicine for protecting liver. According to the compound provided by the invention, as a natural small-molecule compound, (5,7,8,4'-tetrahydroxyflavone)-3'-4-(5,7-dihydroxyflavone) has lower toxicity to normal cells and less side effects; in addition to a good function of protecting the liver, the biflavonoid compound also exhibits significant hepatocellular carcinoma-resistant effects, and the biflavonoid compound can provide a novel therapeutic medicine and therapeutic route for patients with the hepatocellular carcinoma, and has the advantages of a moderate effective dose and significant curative effects, small toxic and side effects; therefore, the biflavonoid compound has broad application prospects.

The present invention relates to a DNA aptamer specifically binding to a hepatocellular carcinoma-related Glypican-3(GPC3) protein, treatment of cancers related to the Glypican-3 protein using the same, a composition for inhibiting a cancer and a composition for diagnosing a cancer comprising the same as an active ingredient.

The present application is directed to compositions and methods for treating a subject with cancer and / or increasing migration of a mesenchymal stromal cells (MSCs) stimulated with a recombinant autocrine motility factor (rAMF) to a tumor or a tumor cell, e.g. hepatocellular carcinoma (HCC). In addition, methods for increasing adhesion of MSCs to endothelial cells with rAMF are disclosed. In some embodiments, the MSCs comprise a therapeutic agent, e.g., an anti-tumor agent.

The hHscFv gene sequences encode the plants. The synthetic DNA includes: the nucleic acid sequence which is 70% same to the 51-812bp nucleic acids of the SEQ IDNO.1 encodes the multi peptides with the hHscFv activity. The sequence encodes the multi peptides with the amino acid sequence of the SEQ ID NO.2. The peptides have the important value for curing the hepatocellular carcinoma.